Revalesio Corporation
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Revalesio Corporation sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Revalesio Corporation: 6 sponsored US clinical trials, none currently recruiting.
Revalesio Corporation sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myocardial Infarct, with 1 trials.
Upper-quartile sponsor footprint
Revalesio Corporation sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
NCT04693715
Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis
NCT02523794
Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma
NCT01511302
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
NCT01264783
Safety Study of Nebulized RNS60 to Treat Asthma.
NCT01057498
Feasibility Study to Evaluate the Safety of Topically Applied Revera in Subjects With Venous Leg Ulcers
NCT00823446
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Therapeutic Areas
How the Revalesio Corporation early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Myocardial Infarct (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Revalesio Corporation: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Revalesio Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Revalesio Corporation page
6 registered trials is a research-attention snapshot, not an endorsement of Revalesio Corporation or any single study.
- None of Revalesio Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Myocardial Infarct is the condition Revalesio Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myocardial Infarct trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Revalesio Corporation pipeline card: 6 registered trials from official public datasets.Report a data error.